SinoMab BioScience Ltd., a Hong Kong-based biopharmaceutical company, has announced the issuance of 112,810,817 new shares under a general mandate. The shares will be issued at a subscription price of HK$1.10 per share. This move is part of a subscription agreement between SinoMab and twenty-six subscribers. The initiative aims to raise capital by leveraging the general mandate, which allows the company to issue new shares up to 20% of its existing issued shares. The announcement was made by the company's Executive Director, Chairman, and CEO, Dr. Shui On Leung.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.